Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor – April 28, 2020 at 7:00 AM EDT
Conclusions:
VOYAGER did not meet the primary endpoint of an improvement in progression-free survival for avapritinib versus regorafenib in patients with third- or fourth-line GIST.
Plan to continue to prioritize portfolio opportunities in systemic mastocytosis and RET-altered cancers, with multiple regulatory submissions anticipated in 2020. Continue to expect existing cash balance to fund operations into the second half of 2022. Blueprint Medicines to host investor conference call and webcast today at 8:00 a.m. ET.
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced top-line results from the Phase 3 VOYAGER clinical trial of avapritinib versus regorafenib in patients with locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST). The VOYAGER trial did not meet the primary endpoint of an improvement in progression-free survival (PFS) for avapritinib versus regorafenib. Top-line safety data for avapritinib were consistent with those previously reported. Read more…
Blueprint Medicines letter to the GIST Community:
